This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look: Examining Provention Bio's Teplizumab as a new treatment to delay onset of clinical Type 1 Diabetes Mellitus
Ticker(s): PRVB, VRTXWho's the expert?
- Pediatric endocrinologist since 1990.
- Person with diabetes since March 1, 1966. CDCES since 1989.
- Clinical Professor of Pediatrics.
- President of 2 non-profit organizations.
- Diabetes Housecall program began in 2006 and is the future of diabetes healthcare delivery as rates of diabetes skyrocket and providers struggle to keep up with clinical demands on their time and expertise.
Interview GoalThis conversation will focus on TN-10 trial data for PRVB's Teplizumab in type 1 diabetes currently under FDA review following a refiled BLA.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
